Restoration of endogenous C-peptide by islet transplantation is associated with increased duration of normoglycaemia and reduced blood glucose variability in recipients with Type 1 Diabetes

Augustin Brooks, A Aldibbiat, Denise Bennett, Julie Wardle, Charlotte Gordon, Mark Walker, Jim Shaw

Research output: Contribution to conferencePosterpeer-review

Abstract

Aims: The Diabetes Control and Complications Trial reported that maintained C-peptide production benefits blood glucose control in individuals with Type 1 diabetes. We investigated whether restoration of endogenous C-peptide production by islet transplantation improved blood glucose control, and whether loss of C-peptide below a given threshold reduced clinical benefit.
Methods: Ten UK islet recipients [age (mean ± SD) 52.3 ± 6.8years, 90% female] had continuous glucose monitoring (CGM) for five to seven days pre-transplant and one, three and six months post-transplant. At each follow-up, graft function was determined by 90min C-peptide during a meal tolerance test (MTT90). Blood glucose <3mmol/l was considered hypoglycaemic and >10mmol/l hyperglycaemic. Blood glucose variability was assessed by standard deviation from mean glucose. Outcomes were compared in recipients with MTT90>200pmol/l vs<200pmol/l.
Results: Islet graft function with MTT90>200pmol/l was established in 80%, 80% and 70% of recipients at one, three and six months post-transplant respectively. Recipients achieving MTT90>200pmol/l spent more time normoglycaemic post-transplant (48.6% pre- vs 80.9%, 77.7%, 82.9% at one, three and six months post-transplant, p<0.01) and less time hyperglycaemic (42.8% pre- vs 16.2% six months post-transplant, p<0.03). Mean blood glucose variability was significantly reduced in individuals with MTT90>200pmol/l compared with pre-transplant (2.2mmol/l vs 4.1mmol/l, p<0.01) and individuals with MTT90<200pmol/l (4.0mmol/l, p<0.01), who failed to sustain significant improvement in variability compared with pre-transplant (p=0.86).
Conclusions: Stimulated C-peptide>200pmol/l was associated with reduced hyperglycaemia and blood glucose variability post-islet transplant. Therapies aimed at maintaining/restoring endogenous C-peptide production need to consider the thresholds required for clinical benefit.
Original languageEnglish
Pages75
Number of pages1
DOIs
Publication statusPublished - 13 Mar 2013
EventDiabetes UK Professional Conference 2013 - Manchester
Duration: 1 Mar 2013 → …

Conference

ConferenceDiabetes UK Professional Conference 2013
Period1/03/13 → …

Fingerprint Dive into the research topics of 'Restoration of endogenous C-peptide by islet transplantation is associated with increased duration of normoglycaemia and reduced blood glucose variability in recipients with Type 1 Diabetes'. Together they form a unique fingerprint.

Cite this